By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.
For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.
Read our latest news
A push-button, automated solution for profiling cell health and death Nanolive launches another ground-breaking tool in cell analysis: the LIVE Cell Death Assay, a push button, automated solution for profiling cell health, death, apoptosis and necrosis, label-free....
We are very proud and excited to announce a new publication from Dr. José Padrón and lead author Adrián Puerta showing the benefits of using Nanolive’s label-free data analysis in Phenotypic Drug Discovery (PPD) programs. Dr. Padrón is a Professor at the Universidad...
For the launch of our new digital assay, the Smart Lipid Droplet Assay, several key opinion leaders from various pharmaceutical companies and institutions had the chance to try out Nanolive's new tool first hand. Check below how they’ve put the new tool to use, and...
3D CELL EXPLORER
Budget-friendly, easy-to-use, compact solution for high quality non-invasive 4D live cell imaging
3D CELL EXPLORER-fluo
Multimodal Complete Solution: combine high quality non-invasive 4D live cell imaging with fluorescence